PROTO SCRIPT PHARMACEUTICAL CORP

As of September 30, 2017, PROTO SCRIPT PHARMACEUTICAL CORP carries a market capitalization of 1.87M, placing it among publicly traded companies globally. Its enterprise value stands at 2.24M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2017, PROTO SCRIPT PHARMACEUTICAL CORP has 49.14M shares outstanding.

These figures are as of September 30, 2017. The price-to-sales ratio is 9.31, and the price-to-book ratio stands at -1.29.

These figures are as of September 30, 2017. The EV/Sales ratio of 3.71 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.24M versus a market cap of 1.87M, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2017, PROTO SCRIPT PHARMACEUTICAL CORP maintains a current ratio of 0.11, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -25.85, indicating conservative leverage, while an interest coverage ratio of -1.49 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2017. Return on assets (ROA) is negative at -3,329.99, reflecting losses generated across the asset base. The company generates approximately 46,536.77 in revenue per employee across its workforce of 13.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended September 30, 2017, PROTO SCRIPT PHARMACEUTICAL CORP generated 604,978.00 in revenue and converted that into -8.39M in net income, yielding earnings per share of -0.06. EBITDA reached -962,569.00, while operating income came in at -970,952.00.

As of September 30, 2017, PROTO SCRIPT PHARMACEUTICAL CORP holds - - in cash and equivalents against 372,745.00 in total debt, resulting in a net debt position of 372,745.00. Total book value stands at -1.44M, with working capital of -1.49M providing operational flexibility.

PROTO SCRIPT PHARMACEUTICAL CORP produced -303,097.00 in operating cash flow over the twelve months ended September 30, 2017. After subtracting -33,847.00 in capital expenditures, free cash flow totaled -336,944.00 - equivalent to 0.00 per share.

Over the twelve months ended September 30, 2017, PROTO SCRIPT PHARMACEUTICAL CORP posted a gross margin of 58.15, reflecting its pricing power and cost economics. The operating margin of -160.49 and net profit margin of -1,386.22 provide insight into operational efficiency.

Over the twelve months ended September 30, 2017, PROTO SCRIPT PHARMACEUTICAL CORP paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -5.98: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -17.73, meaning PROTO SCRIPT PHARMACEUTICAL CORP raised more capital through share issuance and new debt than it returned via dividends and buybacks.

PROTO SCRIPT PHARMACEUTICAL CORP's most recent stock split took place on October 21, 2016 with a 1:10 split ratio.

As of September 30, 2017, PROTO SCRIPT PHARMACEUTICAL CORP has an Altman Z-Score of -70.19, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.